Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
about
Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA RegistryBenefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry.An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting.Clinical management of patients with hypertension and high cardiovascular risk: main results of an Italian survey on blood pressure control.Guideline adherence in cardiovascular risk assessment and analysis in 15,000 hypertensive German patients in real life: results of the Prospective 3A Registry.The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry.Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study.
P2860
Q36639121-E3B56183-9A3F-46D9-AB86-C30FAA34A213Q40791761-41913A91-E751-4EE4-B162-94CC154A5D62Q42662070-7E7401A9-6CF9-4BFB-BDA4-3CAADA95FB41Q43761552-7A035EF1-9145-4373-9062-6887864B5975Q44234583-9BF117A2-0BD7-4F0B-AD74-C92D776600F5Q44633125-7EA34902-96C5-44AB-9C73-9CA05B1C7116Q48265147-9F1CC887-9BD7-43AF-A083-74438E09A7BCQ52860398-03027FEC-FADA-4643-8060-9A9AAB5368D4
P2860
Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Aliskiren for the treatment of ...... f the prospective 3A registry.
@ast
Aliskiren for the treatment of ...... f the prospective 3A registry.
@en
Aliskiren for the treatment of ...... f the prospective 3A registry.
@nl
type
label
Aliskiren for the treatment of ...... f the prospective 3A registry.
@ast
Aliskiren for the treatment of ...... f the prospective 3A registry.
@en
Aliskiren for the treatment of ...... f the prospective 3A registry.
@nl
prefLabel
Aliskiren for the treatment of ...... f the prospective 3A registry.
@ast
Aliskiren for the treatment of ...... f the prospective 3A registry.
@en
Aliskiren for the treatment of ...... f the prospective 3A registry.
@nl
P2093
P2860
P1476
Aliskiren for the treatment of ...... f the prospective 3A registry.
@en
P2093
3A Registry Investigators
R Schmieder
P2860
P304
P356
10.1111/J.1742-1241.2012.02893.X
P577
2012-02-09T00:00:00Z